Guardian Pharmacy Services, Inc. Class A (GRDN) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Allen Lutz reiterated a Buy rating on Guardian Pharmacy Services, Inc. Class A today and set a price target of $42.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Lutz is a 5-star analyst with an average return of 10.0% and a 62.32% success rate. Lutz covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, Teladoc, and Healthequity.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Guardian Pharmacy Services, Inc. Class A with a $43.00 average price target.
Based on Guardian Pharmacy Services, Inc. Class A’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $397.62 million and a net profit of $20.92 million. In comparison, last year the company earned a revenue of $338.57 million and had a net profit of $11.94 million
Based on the recent corporate insider activity of 42 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GRDN in relation to earlier this year.
Read More on GRDN:
Disclaimer & DisclosureReport an Issue
- Guardian Pharmacy files automatic Class A common stock offering
- Guardian Pharmacy reports Q1 EPS 29c, consensus 24c
- Guardian Pharmacy affirms FY26 revenue view of $1.40B-$1.42B, consensus $1.42B
- Guardian Pharmacy initiated with a Buy at BofA
- Guardian Pharmacy price target raised to $43 from $38 at Truist
